Leerink on Acadia (ACAD): 'Despite the news, we still like the stock'
Tweet Send to a Friend
Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $32.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
